摘要
目的研究探讨盐酸贝那普利在冠心病心力衰竭患者治疗中的应用效果。方法系统性回顾2016年3月~2017年2月于我院心内科收治入院的60例冠心病心力衰竭患者,将所有患者依据治疗方式不同分成两组,每组30例。给予对照组常规治疗,实验组在对照组基础上加服盐酸贝那普利。全部病例规律治疗,定期随访1年,检查心电图与心脏彩超,对比左心室射血分数(LVEF)和左心房内径心脏指标及新发房颤发生情况。结果两组患者治疗前的LVEF、左心房内径、左室收缩末期内径比较,差异无统计学意义(P>0.05);两组患者治疗后的LVEF、左室收缩末期内径均显著高于治疗前,左心房内径显著低于治疗前(P<0.05),且实验组治疗后的LVEF、左室收缩末期内径均显著高于对照组,左心房内径显著低于对照组(P<0.05)。实验组的新发房颤发生率为13.33%,显著低于对照组的36.67%(P<0.05)。结论盐酸贝那普利治疗冠心病心力衰竭患者能显著改善患者的心功能,降低新发房颤的发生率,效果显著,值得临床推广应用。
Objective To investigate application effect of Benazepril Hydrochloride in the treatment of patients with coronary heart disease and heart failure.Methods All of 60 patients with coronary heart disease and heart failure treated in our hospital from March 2016 to February 2017 was systematically reviewed.All patients were divided into the two groups according to different treatment methods,and 30 patients in each group.The control group was given routine treatment while the experimental group was given Benazepril Hydrochlorid on the basis of the control group.All patients were treated regularly and followed up for 1 year.Electrocardiogram and color Doppler echocardiography were performed to compare the left ventricular ejection fraction (LVEF),left atrial diameter and the incidence of new onset atrial fibrillation.Results There was no significant difference in LVEF,inner diameter of left atrium and left ventricle end-systolic diameter before treatment in patients between the two groups (P>0.05).LVEF and left ventricular end-systolic diameter in patients of both groups after treatment were significantly higher than those before treatment,and the inner diameter of left atrium was significantly lower than that before treatment (P<0.05),and LVEF and left ventricular end-systolic diameter in the experimental group after treatment were significantly higher than those in the control group,and the inner diameter of left atrium was significantly lower than that of the control group (P<0.05).The incidence of new onset atrial fibrillation in the experimental group was 13.33%,which was significantly lower than that in the control group (36.67%)(P<0.05).Conclusion Benazepril Hydrochloride in the treatment of patients with coronary heart disease and heart failure can significantly improve the cardiac function of patients,reduce the incidence of new onset atrial fibrillation,and has significant curative effect,which is worthy of clinical promotion and application.
作者
张勇
ZHANG Yong(Ward Three of Cardiovascular Medicine Department,Gaozhou People′s Hospital,Guangdong Province,Gaozhou 525200,China)
出处
《中国当代医药》
2019年第22期34-36,共3页
China Modern Medicine
关键词
盐酸贝那普利
冠心病
心力衰竭
新发房颤
Benazepril Hydrochlorid
Coronary heart disease
Heart failure
New onset atrial fibrillation
